Can B12 and Folate Levels Predict HPV Penetration in Patients With ASCUS?

Sanliurfa Mehmet Akif Inan Education and Research Hospital

Status: Completed

Conditions: Human Papilloma Virus; ASC-US

Treatments: Dietary Supplement: Vitamin B12 and folate

Study type: Interventional

Funder types: Other

Identifiers

NCT03903952

714

Details and patient eligibility

About

Non-classified atypical squamous cells (ASCUS) is the most common abnormal cervical cytology (%39). The risk of cervical intraepithelial neoplasia 2-3 is 5% and the risk of carcinoma is around 0.1% after diagnosis. Mostly human papillomavirus (HPV) is responsible for this transition. Most of them are transient, but some infections become persistent and can progress into precancer and invasive cancer. In the process of progression to cancer; patients with cell cycle problems are thought to be at risk. In some studies, B12 and folate deficiency, which play a role in DNA synthesis and repair, have been shown to induce incorrect binding of uracil to DNA, leading to DNA breakage and repair disorder. Therefore, in this study, it has been aimed that the relation of presence of atypical squamous cells and HPV persistence with folate and vitamin B12 levels which effect on immune system.

Full description

Participants were divided into two groups according to their smear results; atypical squamous cells of undetermined significance (ASCUS) (study group: 100 patients) and women who did not have intraepithelial neoplasia as a result of smear (control group: 100 patients). Patients who had well preserved sufficient number of squamous epithelial cells, who did not have bleeding, fixation failure, inflammation or atrophy, and had negative cervical cytology smear were considered as control group. HPV test was also requested from the study group. B12 and folate blood levels were compared between the groups.

Enrollment: 200 patients

Sex: Female

Ages: 30 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• female patients aged between 30-65 who were undergoing smear tests with the aim of control
• body mass index (BMI) lower than 35
• Participants did not have any chronic diseases

Exclusion criteria

• Patients taking B12 and folate supplement due to mix type anemia
• patients taking active vitamin B12 and folate-containing vitamin supplements
• pregnant women
• women with other cervical intraepithelial lesions such as low grade squamous intraepithelial lesion (LGSIL), high grade squamous intraepithelial lesion (HGSIL) or high grade squamous intraepithelial lesion can not be excluded (ASC-H) in smear
• patients with cervical cancer diagnosis
• patients who were operated due to cervical cancer
• patients who had HPV vaccine
• patients with a diagnosis that can inhibit B12 and folate absorption in gastro-intestinal tract
• vegetarians

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

200 participants in 2 patient groups

Papanicolaou smear result (control group)

Other group

Description:

women who did not have intraepithelial neoplasia as a result of smear

Treatment:

Dietary Supplement: Vitamin B12 and folate

Papanicolaou smear result (study group)

Other group

Description:

women who have atypical squamous cells of undetermined significance (ASCUS) as a result of smear

Treatment:

Dietary Supplement: Vitamin B12 and folate